Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02199665
What this trial is testing

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
University of Chicago 52
Not applicableUnknownNCT05308875
What this trial is testing

Efficacy and Safety Evaluation of PD1-BCMA-CART

Who this might be right for
Multiple Myeloma
Bioray Laboratories 9
Early research (Phase 1)Temporarily pausedNCT07340853
What this trial is testing

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Thomas Martin, MD 30
Not applicableEnded earlyNCT00813501
What this trial is testing

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseInfection+7 more
City of Hope Medical Center 60
Testing effectiveness (Phase 2)Looking for participantsNCT07657312
What this trial is testing

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Who this might be right for
Cytokine Release SyndromeRecurrent Multiple MyelomaRefractory Multiple Myeloma
Naresh Bumma 35
Testing effectiveness (Phase 2)Ended earlyNCT04407442
What this trial is testing

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
University of California, San Francisco 5
Early research (Phase 1)Study completedNCT03733717
What this trial is testing

Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sanofi 25
Early research (Phase 1)Ended earlyNCT02978235
What this trial is testing

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Who this might be right for
Multiple MyelomaNonHodgkin Lymphoma
Taiho Oncology, Inc. 11
Testing effectiveness (Phase 2)Study completedNCT02046915
What this trial is testing

Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide

Who this might be right for
Relapsed or Refractory Multiple Myeloma
University Hospital Tuebingen 60
Not applicableNo Longer AvailableNCT02204553
What this trial is testing

Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals
Early research (Phase 1)UnknownNCT04818372
What this trial is testing

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Who this might be right for
Multiple MyelomaLymphoma
Keymed Biosciences Co.Ltd 87
Testing effectiveness (Phase 2)Active Not RecruitingNCT03589222
What this trial is testing

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
PETHEMA Foundation 62
Testing effectiveness (Phase 2)Study completedNCT00474929
What this trial is testing

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Who this might be right for
LymphomaMultiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 103
Early research (Phase 1)Study completedNCT06082596
What this trial is testing

Study of BEBT-908 in Subjects With Advanced Hematological Tumors

Who this might be right for
Relapsed or Refractory Non-Hodgkin's LymphomaRelapsed or Refractory Multiple Myeloma
BeBetter Med Inc 32
Testing effectiveness (Phase 2)Ended earlyNCT02952573
What this trial is testing

Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

Who this might be right for
Multiple MyelomaRelapsed/Refractory
University Health Network, Toronto 20
Testing effectiveness (Phase 2)Study completedNCT00966693
What this trial is testing

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
M.D. Anderson Cancer Center 77
Testing effectiveness (Phase 2)Study completedNCT02159365
What this trial is testing

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 84
Early research (Phase 1)Study completedNCT05567887
What this trial is testing

Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

Who this might be right for
LymphomaMultiple Myeloma
Pfizer 7
Early research (Phase 1)Ended earlyNCT00744354
What this trial is testing

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
UNC Lineberger Comprehensive Cancer Center 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07107204
What this trial is testing

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed or Refractory Hematologic MalignanciesLeukemiaLymphoma+1 more
Biotroy Therapeutics 116
Next Page